فارسی
Driver mutations are mutations that play a fundamental role in activating signaling pathways in cells and lead to clinical changes in diseases. Patients with myeloproliferative neoplasms (MPN) have driver mutations in JAK2, MPL, or CALR genes, which activate the thrombopoietin receptor (TPOR) and downstream signaling pathways. JAK2 mutation is associated with permanent activation of TPOR, erythropoietin signaling (EPOR), and colony-stimulating factor 3 receptor (CSF3R).
The MPL gene is a proto-oncogene that encodes TPOR, the growth factor receptor for hematopoietic stem cells. MPL mutations cause stable TPOR dimerization, which activates JAK2 and the thrombopoietin pathway. The thrombopoietin pathway plays an important role in the development of megakaryocytes and platelets, as well as self-renewal of hematopoietic stem cells. MPL mutations are associated with diseases such as essential thrombocytopenia, primary myelofibrosis, and amegakaryocytic thrombocytopenia, which are genetic disorders in platelet production.
TPOR is a key player in the development of MPN, and MPL mutations are of great importance in fully elucidating the molecular mechanisms of clinical symptoms of MPN and developing new targeted therapeutic strategies to cut off the dysregulated signaling chain. The MPL gene codes for the thrombopoietin receptor protein, which helps in the growth and division of platelets. The MPL test is a genetic test that can identify mutations in the MPL gene using exon genetic sequencing technology. This test is used to diagnose platelet disorders that are a group of genetic diseases that cause excessive and uncontrolled bleeding.
